Associate Director for Regulatory Affairs, OHOP and OCE (Acting), CDER, FDA
Tamy Kim is the Associate Director for Regulatory Affairs (ADRA) in the Office of Oncology and Hematology Products (OHOP) and Acting ADRA in the Oncology Center of Excellence (OCE) at the FDA. In OHOP, her responsibilities include developing policies related to review processes...
Read More →
Associate Director for Patient Outcomes (Acting), OCE, FDA
Paul G. Kluetz, M.D., is a medical oncologist and the Acting Associate Director of Patient Outcomes in the Oncology Center of Excellence at the U.S. FDA. He is interested in defining clinical benefit in oncology trials, the use of expedited programs such as accelerated approval a...
Read More →AK
Acting Deputy Director, Office of Device Evaluation, CDRH, FDA
Director, Center for Biologics Evaluation and Research, FDA
Served as Clinical Director of Hematology at Brigham and Women's Hospital, worked in the pharmaceutical industry on the clinical development of hematology and oncology products, led the Adult Leukemia Service and served as Chief Clinical Officer of Smilow Cancer Hospital. He join...
Read More →
Deputy Director, Regulatory Programs, OCD, CDER, FDA
As Deputy Director for Regulatory Programs, Dr. Throckmorton shares the responsibility for overseeing the regulation of research, development, manufacture and marketing of prescription, over-the-counter, and generic drugs in the United States.
Associate Director, Policy and Product Classification Officer, OCP, OC, FDA
John Barlow Weiner is the Associate Director for Policy in the Office of Combination Products. Prior to joining OCP, Mr. Weiner was an Associate Chief Counsel in FDA's Office of Chief Counsel and in private practice. He received a BA from Princeton University and a JD with honors...
Read More →
